Lyell Immunopharma, Inc. (NASDAQ:LYEL) CFO Charles W. Newton Acquires 200,000 Shares

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CFO Charles W. Newton acquired 200,000 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were purchased at an average price of $0.56 per share, with a total value of $112,000.00. Following the completion of the transaction, the chief financial officer now owns 200,000 shares of the company’s stock, valued at $112,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Lyell Immunopharma Stock Up 20.3 %

LYEL opened at $0.58 on Thursday. Lyell Immunopharma, Inc. has a twelve month low of $0.48 and a twelve month high of $3.15. The company has a fifty day moving average of $0.62 and a 200-day moving average of $0.89. The stock has a market cap of $171.76 million, a PE ratio of -0.74 and a beta of -0.41.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). The company had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. Sell-side analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of large investors have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio acquired a new stake in Lyell Immunopharma in the fourth quarter worth $64,000. venBio Partners LLC acquired a new stake in Lyell Immunopharma in the fourth quarter worth $4,545,000. Two Sigma Advisers LP grew its holdings in Lyell Immunopharma by 143.8% in the fourth quarter. Two Sigma Advisers LP now owns 306,400 shares of the company’s stock worth $196,000 after purchasing an additional 180,700 shares during the period. Millennium Management LLC lifted its stake in shares of Lyell Immunopharma by 34.8% in the fourth quarter. Millennium Management LLC now owns 957,507 shares of the company’s stock valued at $613,000 after buying an additional 247,440 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Lyell Immunopharma by 13.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 308,551 shares of the company’s stock valued at $197,000 after buying an additional 36,555 shares in the last quarter. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating and set a $1.00 price objective on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.